Unlocking the potential: the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) as biomarkers informing immunotherapy outcomes in lung cancer patients — single oncology center experience and literature review
- 21 August 2024
- journal article
- research article
- Published by VM Media Group sp. z o.o in Oncology in Clinical Practice
- Vol. 20 (4) , 278-285
Abstract
Introduction. The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), two promising biomarkers of effectiveness of cancer immunotherapy, have obtained great attention in recent years. The NLR and PLR are both simple and readily available markers derived from routine blood tests. It is postulated that integrating these biomarkers into clinical practice could facilitate monitoring immunotherapy effects. In this study, we retrospectively examined NLR and PLR values in non-small cell lung cancer patients (NSCLC) receiving second-line immunotherapy. Material and methods. The study group included 73 NSCLC patients: 38 men and 35 women. Twenty-three patients were diagnosed with squamous cell carcinoma (SqCC), and 50 patients with non-squamous cell carcinoma (non-SqCC). We assessed NLR and PLR values at immunotherapy initiation (NLR1, PLR1) and after 3 months of the follow-up (NLR2 and PLR2). These parameters were correlated with the clinical characteristics of patients, response to treatment, progression-free survival (PFS), and overall survival (OS). Results. The values of PLR1 and delta PLR were significantly higher in non-SqCC patients compared to SqCC patients. Other clinical and demographic factors did not influence the values of NLR1, NLR2, PLR2, or delta NLR. Medians of NLR1 and NLR2 were significantly lower in patients with controlled disease than in patients with disease progression. Patients with PFS longer than 12 months had a significantly lower median NLR2 than patients with PFS shorter than 1 year. A factor that significantly increased the risk of progression and death was a high NLR2 value. Conclusions. NLR and PLR represent promising biomarkers for monitoring immunotherapy effectiveness in cancer patients, which offer insights into the dynamic interplay between the host immune system and tumor biology. Further research is warranted to validate their utility in larger patient cohorts and standardize their incorporation into clinical practice. Keywords: non-small cell lung cancer predictive factors immunotherapy neutrophils-to-lymphocytes ratio platelet-to-lymphocyte ratioKeywords
This publication has 15 references indexed in Scilit:
- Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysisiScience, 2023
- Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapyJournal for ImmunoTherapy of Cancer, 2022
- Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancerJournal for ImmunoTherapy of Cancer, 2021
- PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategyCritical Reviews in Oncology/Hematology, 2021
- PD-L1 as a biomarker of response to immune-checkpoint inhibitorsNature Reviews Clinical Oncology, 2021
- A decade of immune-checkpoint inhibitors in cancer therapyNature Communications, 2020
- Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumabJournal of Clinical Laboratory Analysis, 2019
- Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 BlockadeBioMed Research International, 2017
- Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancerLung Cancer, 2017
- Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinomaBMC Urology, 2017